Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis
Endocrine Connections · 2025-09-01 · 14 (9)
DOI: 10.1530/ec-25-0247 ↗Abstract
Graphical Abstract Abstract Objective Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels. Design Retrospective cohort analysis of ACROSTUDY, a global surveillance study of patients with acromegaly receiving pegvisomant. Methods Cumulative incidence function was used to estimate disease-specific mortality, and regression analyses to characterized risk factors. Disease-specific standardized mortality ratios (SMR) were calculated; Poisson regression models characterized the association between disease-specific SMR, IGF-I, and other risk factors. Results 2077 patients were followed (median: 4.1 years). Mortality (HR, 95% CI) secondary to cardiovascular/cerebrovascular causes increased with higher on-treatment IGF-I (1.97 (1.45–2.67), P < 0.0001) and older age at enrollment (1.10 (1.07–1.13), P < 0.0001). Mortality secondary to malignant (1.57 (1.17–2.09), P = 0.0024) or respiratory (1.64 (1.23–2.19), P = 0.0008) causes increased with higher on-treatment IGF-I. Younger attained age (0.93 (0.91–0.96), P < 0.0001), younger age (<35 vs > 50 years) at diagnosis (3.64 (1.33–9.93), P = 0.0117), higher on-treatment IGF-I (1.69 (1.12–2.55), P = 0.0127), and pituitary radiotherapy (2.25 (1.09–4.63), P = 0.0280) were associated with higher SMR (95% CI) for cardiovascular/cerebrovascular causes. Younger attained age (0.93 (0.89–0.96), P < 0.0001), higher IGF-I at enrollment (>2 × vs <1 × upper limit of normal: 4.89 (1.09–21.8), P = 0.0378), and malignancy at enrollment (7.05 (2.36–21.03), P = 0.0005) were associated with higher SMR (95% CI) for malignant causes. Younger age (35–50 vs >50 years) at diagnosis (4.50 (1.08–18.83), P = 0.0394) and sleep apnea (4.98 (1.34–18.53), P = 0.0168) were associated with higher SMR ratios for respiratory causes. Conclusions Younger age, higher on-therapy IGF-I, and radiotherapy were associated with higher SMR for cardiovascular/cerebrovascular causes, highlighting the importance of achieving IGF-I normalization.
EUVIMED